• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

    11/14/24 3:54:54 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care
    Get the next $BJDX alert in real time by email
    SC 13G/A 1 armistice-bjdx093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Bluejay Diagnostics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    095633400

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  095633400
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    347,697
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    347,697
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    347,697
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.99%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  095633400
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    347,697
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    347,697
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    347,697
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.99%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 095633400
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Bluejay Diagnostics, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    360 Massachusetts Avenue, Suite 203

    Acton, MA 01720

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    095633400

     

    CUSIP No.  095633400
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 095633400
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 30, 2024:

    Armistice Capital, LLC - 347,697

    Steven Boyd - 347,697   

    (b) Percent of Class as of September 30, 2024:

    Armistice Capital, LLC - 4.99%

    Steven Boyd - 4.99% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 347,697

    Steven Boyd - 347,697  

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 347,697

    Steven Boyd - 347,697

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 095633400
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 095633400
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $BJDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BJDX

    DatePrice TargetRatingAnalyst
    1/12/2022$10.00Buy
    Dawson James
    More analyst ratings

    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

      ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update. Recent Business Highlights and Developments: SYMON Clinical Program Update: The Company has initiated its pivotal SYMON-II clinical study, following the successful completion of the SYMON-I pilot study, for which a primary analysis highlighted that IL-6 levels within 24 hours of ICU admission may predict sepsis patient mortality out to 28 days. Currently, the Company is collecting, freezing and biobanking samples, w

      6/3/25 4:05:00 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

      ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6) in sepsis patients intended or admitted for the intensive care unit (ICU), will be presented. SYMON-I evaluated IL-6 as a prognosticator for 28-day mortality and exploratory endpoints including 7-day mortality and microbiological positivity. "Early use of IL-6 in sepsis and septic shock pat

      4/15/25 7:00:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

      ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase up 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share, resulting in gross proceeds of approximately $3.7 million, before deducting

      4/7/25 5:21:14 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    SEC Filings

    See more
    • Bluejay Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/28/25 5:18:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Bluejay Diagnostics Inc.

      DEF 14A - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/16/25 5:00:34 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Bluejay Diagnostics Inc.

      10-Q - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/13/25 4:01:45 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dawson James initiated coverage on Bluejay Diagnostics with a new price target

      Dawson James initiated coverage of Bluejay Diagnostics with a rating of Buy and set a new price target of $10.00

      1/12/22 9:00:51 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

      ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin "Ed" E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer. Mr. Rule is a highly credentialed regulatory, quality and compliance professional with more than 15 years of industry experience. He has extensive training and expertise in medical device regulations in the U.S. and numerous international markets.

      3/28/22 7:00:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

      ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay") a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company. "I am very pleased to welcome Mark on board as Chief Medical Advisor. I believe Mark's expansive clinical background and strategic leadership skills will be invaluable as we seek to develop the Compa

      1/5/22 8:15:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bluejay Diagnostics Inc.

      SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      11/14/24 5:49:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

      SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      11/14/24 3:54:54 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Bluejay Diagnostics Inc.

      SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      7/3/24 4:01:01 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:17:42 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:16:33 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Scally Frances P

      3 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      10/11/23 7:21:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:17:42 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:16:33 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care